(Q27693823)

Schmidt D

series ordinal

2

1 reference

publication date

April 2011

1 reference

1 reference

52

1 reference

issue

4

1 reference

page(s)

657-78

1 reference

Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

The little compound that could: how phenytoin changed drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Conversion to monotherapy: clinical trials in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Key factors in the discovery and development of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Seizure reduction and quality of life improvements in people with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Likelihood of seizure remission in an adult population with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

What is an epileptic seizure? Unifying definitions in clinical practice and animal research to develop novel treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Posttraumatic epilepsy: the challenge of translating discoveries in the laboratory to pathways to a cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Beta-blockers in heart failure: promising or proved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Modern management of epilepsy: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Levetiracetam for managing neurologic and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Seizures after primary intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Levetiracetam in spinal cord injury pain: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Historical control monotherapy design in the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Innovative designs of controlled clinical trials in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

21 January 2018

Posttraumatic epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Use of epileptic animals for adverse effect testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Antiepileptic Drug Development: I. History and a Program for Progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Antiepileptic drug development: II. Anticonvulsant drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Refractory gastro-oesophageal reflux disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Animal models of intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

New visions in the pharmacology of anticonvulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Current status and future directions in the pharmacotherapy of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Functional, metabolic, and synaptic changes after seizures as potential targets for antiepileptic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

New horizons in the development of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Identification and preclinical testing of novel antiepileptic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Outcomes in newly diagnosed localization-related epilepsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Negative effects of antiepileptic drugs on mood in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Development of new antiepileptic drugs: challenges, incentives, and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Therapeutic approaches to epileptogenesis--hope on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Epileptogenesis in the immature brain: emerging mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Molecular and cellular mechanisms of pharmacoresistance in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Intrinsic severity as a determinant of antiepileptic drug refractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

The neurobiology of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Kindling: basic mechanisms and clinical validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Quantifying the response to antiepileptic drugs: effect of past treatment history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Drug treatment of epilepsy: options and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Efficacy of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

New developments in antiepileptic drug resistance: an integrative view

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Mechanisms of antiepileptic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Discovery of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Teratogenic effects of antiepileptic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Preclinical development of antiepileptic drugs: past, present, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

21 January 2018

Vigabatrin: 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Invited Article: Comparative effectiveness research, evidence-based medicine, and the AAN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2011.03024.X